# OnCo record nct04901741 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04901741/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04901741", "NCT04901741" ;
  schema:name "Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer"@en ;
  schema:alternateName "OPTIMUS"@en ;
  schema:description "A phase 2 trial of pembrolizumab in pancreatic cancer, run by TME Pharma AG, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04901741/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04901741> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> .